J&J Is In Talks to Sell Its Hips-and-Knees Business to Apollo for $20 Billion
The story in brief
Johnson & Johnson is reportedly negotiating to divest its orthopaedic joint replacement division to Apollo Global Management. The proposed transaction, valued at approximately twenty billion dollars, signals a significant restructuring within the healthcare sector. This move isolates the hips-and-knees business from J&J’s broader pharmaceutical and medical device portfolio. The deal highlights growing investor interest in standalone orthopaedic assets. For professionals, it underscores the volatility of large-cap healthcare holdings and the increasing role of private equity in shaping industry landscapes. Understanding such mergers is crucial for navigating career trajectories in medical devices and corporate strategy.
What this means for your career
This transaction signals a shift towards specialised orthopaedic operations under private equity ownership. You should focus on developing expertise in Mergers and Acquisitions, regulatory compliance, and operational efficiency. Professionals in supply chain management and clinical sales will see heightened demand as Apollo integrates the business. Consider upskilling in financial modelling to understand valuation drivers in healthcare deals. Monitor regulatory changes affecting joint replacement devices, as compliance becomes paramount. Network with peers in medical technology to identify emerging roles in this consolidated market. A smart move is to align your career with firms specialising in healthcare restructuring or orthopaedic innovation. Prepare for potential restructuring by enhancing your adaptability and strategic thinking skills.
Original reporting: WSJ ↗
Build the skills this story demands
Accredited UK qualifications from LSBR, studied 100% online.
